



Republic of the Philippines
Department of Health
FOOD AND DRUG ADMINISTRATION



04 JUN 2021

FDA ADVISORY
No. **2021-1201**

TO : ALL HEALTHCARE PROFESSIONALS AND THE GENERAL PUBLIC

SUBJECT : Public Health Warning Against the Purchase and Use of the Following Unregistered Drug Products:

1. Qingre Sanjie Pian
2. Warmen Relinqing Keli
3. Relinqing Pian
4. Rengongniuhuang Jiaxiaozuo Jiaonang
5. YingRun Ribavirin Eye Drops 8ml:8mg

The Food and Drug Administration (FDA) advises the public against the purchase and use of the following unregistered drug products:



Qingre Sanjie Pian

Figure 1. Unregistered drug product





Warmen Relinqing Keli

Figure 2. Unregistered drug product



Relinqing Pian

by: Hefei Jinyue Pharmaceutical Co., Ltd.

Figure 3. Unregistered drug product

利尔健® 国药准字H22024291

人工牛黄甲硝唑胶囊

RENGONGNIUHUANGJIAXIAOZUO JIAONANG

【适应症】
用于急性智齿冠周炎、
局部牙槽脓肿、牙髓炎、根尖周炎等。

SHUANGYAO GROUP 吉林双药药业集团有限公司



Rengongniuhuang Jiaxiaozuo Jiaonang
by: Shuangyao Group

Figure 4. Unregistered drug product

莹润YingRun® 外

利巴韦林滴眼液

Ribavirin Eye Drops

国药准字H19993421
适用于单纯疱疹病毒性角膜炎。



8 ml:8mg

江苏普华克胜药业有限公司
Jiangsu Puhua Kesheng Pharmaceutical Co., Ltd.

YingRun Ribavirin Eye Drops 8ml:8mg
by: Jiangsu Puhua Kesheng Pharmaceutical Co., Ltd.

Figure 5. Unregistered drug product

FDA Post-Marketing Surveillance (PMS) activities have verified that the abovementioned drug products have not gone through the registration process of the Agency and have not been issued with proper authorization in the form of Certificate of Product Registration. Thus, the Agency cannot guarantee its quality, safety and efficacy. Therefore, consumption of such violative products may pose potential danger or injury to health.


Pursuant to Republic Act No. 9711, otherwise known as the "Food and Drug Administration Act of 2009", the manufacture, importation, exportation, sale, offering for sale, distribution, transfer, promotion, advertising or sponsorship of health products without proper authorization from FDA is prohibited.

All concerned establishments and/or entities are warned not to distribute the above-identified violative drug products until they have already been covered by the appropriate authorization, otherwise, regulatory actions and sanctions shall be strictly pursued.

All Local Government Units (LGUs) and Law Enforcement Agencies (LEAs) are requested to ensure that these products are not sold or made available in their localities or areas of jurisdiction.

For more information and inquiries, please e-mail us at info@fda.gov.ph. To report continuous sale or distribution of unregistered health products, kindly e-mail us via ereport@fda.gov.ph. You may also call the Center for Drug Regulation and Research at telephone number (02) 8809-5596. For any suspected adverse drug reaction (ADR), report immediately to FDA through this link: <https://primaryreporting.who-umc.org/Reporting/Reporter?OrganizationID=PH> and fill out all the required fields.

Dissemination of the information to all concerned is requested.


ROLANDO ENRIQUE D. DOMINGO, MD
Director General

DTN: 
20210525145352